DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Comparison of Topical Antiviral Agents for Labial Cold Sores (Herpes Labialis)

Information source: Hadassah Medical Organization
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Reccurent Herpes Labialis

Intervention: Acyclovir 5% (Drug); Docosanol 10% (Drug); Superlysine gel (Device)

Phase: Phase 4

Status: Not yet recruiting

Sponsored by: Hadassah Medical Organization

Official(s) and/or principal investigator(s):
Doron Aframian, DMD,PhD, Study Chair, Affiliation: Salivary Gland Clinic, Department of Oral Medicine The Hebrew University-Hadassah School of Dental Medicine Jerusalem, Israel P.O.B 12272, Zip code 91120

Overall contact:
Doron J Aframian, DMD, PhD, Phone: 0097226776151, Email: Daframian@yahoo.com

Summary

Recurrent cold sores - herpes simplex labialis (HSL) occurs in 20-40% of the US population

and patient seek treatment because of the discomfort and visibility of the lesion although it is a self limiting disease. The purpose of this study is to check the safety, Efficacy and convenience of Use of the Natural Agent "Superlysin Gel" as Treatment for Herpes Labialis in Comparison to Acyclovir 5% and Docozanole 10%.

Clinical Details

Official title: The Safety, Efficacy and Convenience of Use of the Natural Agent "Superlysin Gel" as Treatment for Herpes Labialis in Comparison to Acyclovir 5% and Docozanole 10%.

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Primary outcome: Reducing healing process and duration of cold sores using superlysin gel

Detailed description: Study design:

- Double blinded non-inferiority prospective parallel-group, intend to treat trial. Enrolment

of 75 patients (25 randomized for each group). - Approval of the Institutional Ethical

Review Board -

Study design:

- Patient characteristics (selected) and historical information assessment including: Race,

average episode duration from patient history Duration of most recent previous episode Time since last onset of oral-facial herpes simplex Time since first onset of oral-facial herpes simplex Does patient experience localized prodrome?

- Experiment duration; 5 to 10 days

- 4 visits (days 1, 3,6,10)

- 5 application /day for each derivative

- Documentation Metric digital images of localized area signs at each visit Clinical

assessment of prodrome/erythema, papule, vesicle, ulcer, crust, or healed skin (with or without residual erythema) Visual analogue scale (VAS) for subjective assessment of pain, burning, itching or tingling at each visit

- Calculation of primary efficacy end point (time to healing); from the date and time of

the initiation of therapy until the date and time of the clinic visit at which complete resolution of all local signs and symptoms, i. e. the lesion had aborted or complete healing had occurred (censored at day 10)

Eligibility

Minimum age: 18 Years. Maximum age: 70 Years. Gender(s): Both.

Criteria:

Inclusion criteria:

- Signed informed consent

- Age range (yrs) 18-70

- Gender ; Males and females

- Health status; immuno-competent

- Clinical history of HSL with at least two recurrences during the past 12 months. The

most recent previous episode must have healed at least 14 days before screening.

- Less than 12 hours after prodrome initiation (i. e. local erythema w/o blistering,

tingling and or burning sensation, soreness) Exclusion criteria:

- Pregnant women

- Mentally disabled

- No intra-oral lesions, or lesions above the nostrils and below the chin

- No topical steroid use and no systemic antiviral current treatments within 7 days

before the study

- No known allergies to topical cosmetics

- No use cosmetics on or around the mouth during the treatment period

- No concomitant use of systemic corticosteroids or other drugs known to induce immune

stimulation or immune suppression

Locations and Contacts

Doron J Aframian, DMD, PhD, Phone: 0097226776151, Email: Daframian@yahoo.com

Additional Information


Last updated: April 30, 2007

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017